martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

AI Search Startup Exa Labs Raises $250M At $2.2 Billion Valuation, Led By Andreessen Horowitz

View original at finance.yahoo.com
AI Search Startup Exa Labs Raises $250M At $2.2 Billion Valuation, Led By Andreessen Horowitz Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Different AI agents require different retrieval behavior — from go-to-market tools needing broad coverage of people and organizations, to coding assistants relying on precise results from repositories and technical documentation.

    60% confidence
  • Exa Labs will use new capital to train its next generation of models and expand infrastructure capable of handling hundreds of thousands of searches per second.

    60% confidence
  • Competitors built on top of existing search engines will struggle to match Exa's combination of speed, cost efficiency, and retrieval quality.

    60% confidence
  • Exa Labs usage has grown to more than 5,000 businesses since pivoting to an API-first model in early 2023.

    60% confidence
  • AI-driven search demand will surge as more autonomous agents come online.

    60% confidence
  • Exa's search tools are used by more than 400,000 developers.

    60% confidence
  • Exa's crawlers index more than 500 billion URLs and the company has developed its own vector database to support high query volumes.

    60% confidence
  • Building a perfect search engine will be extremely hard. It is also necessary. Information is critical civilizational infrastructure for our new AI reality. If we can build perfect search so that every AI has the highest quality information, then every human will too.

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com